URACIL MUSTARD
LOE ApproachingNDAORALCAPSULEPriority Review
Approved
Sep 1962
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Uracil mustard is an oral small-molecule alkylating agent approved in 1962 for treating hematologic malignancies. The drug functions as a nitrogen mustard derivative that cross-links DNA to inhibit tumor cell proliferation. It represents a legacy chemotherapy class with limited modern clinical application.
LOE Approaching
Minimal commercial infrastructure with zero linked job postings; likely managed by small legacy product team focused on supply continuity rather than growth.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Career opportunities on uracil mustard are extremely limited, with zero currently linked positions and declining commercial relevance. Working on this product typically involves legacy portfolio management, regulatory compliance, and supply continuity rather than career-advancing commercial or development activities.
Product Manager (Legacy Portfolio)Regulatory Affairs Specialist
Worked on URACIL MUSTARD at Takeda? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.